UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Dyne Therapeutics, Inc. $DYN

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 12.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 269,985 shares of the company’s stock after purchasing an additional 30,700 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.14% of Dyne Therapeutics worth $5,996,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Handelsbanken Fonder AB purchased a new stake in Dyne Therapeutics during the 2nd quarter worth approximately $1,182,000. Fisher Asset Management LLC acquired a new position in shares of Dyne Therapeutics in the fourth quarter worth $4,891,000. Royal Bank of Canada increased its position in shares of Dyne Therapeutics by 267.6% during the first quarter. Royal Bank of Canada now owns 68,188 shares of the company’s stock worth $1,236,000 after acquiring an additional 49,641 shares during the period. Cibc World Market Inc. acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at $1,345,000. Finally, Clearbridge Investments LLC acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at $7,976,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock opened at $20.31 on Wednesday. The stock has a market cap of $3.79 billion, a P/E ratio of -6.10 and a beta of 1.08. The company has a fifty day simple moving average of $24.82 and a 200-day simple moving average of $20.49. Dyne Therapeutics, Inc. has a 12-month low of $11.92 and a 12-month high of $27.31. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Equities analysts expect that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Insider Activity

In other news, Director Jason Rhodes sold 2,160,516 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the transaction, the director owned 428,946 shares in the company, valued at approximately $10,723,650. This represents a 83.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 5,658 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total value of $106,823.04. Following the sale, the chief executive officer directly owned 357,507 shares in the company, valued at $6,749,732.16. This trade represents a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 4,150,974 shares of company stock valued at $99,697,629. Insiders own 9.46% of the company’s stock.

Key Headlines Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne announced that it will present additional six- and 12-month data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) at the World Muscle Society and AANEM meetings beginning September 29-30. The data will include comparisons with a matched natural-history cohort and updated safety results. Dyne ACHIEVE trial data announcement
• Positive Sentiment: The ACHIEVE registrational expansion cohort is fully enrolled, and Dyne expects topline results in the first quarter of 2027. DYNE-101 also has FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, supporting the potential for an expedited development path. Quiver Quantitative ACHIEVE summary
• Neutral Sentiment: Call-option activity surged, with traders purchasing approximately 20,532 calls versus average daily volume of about 464. This may reflect speculative expectations for a rebound or upcoming data, but options activity does not confirm a fundamental improvement.
• Negative Sentiment: Reports said DYN fell heavily after a rival DM1 drug failed in Phase 3. Investors appear concerned that the setback could signal clinical or commercial risks for the DM1 field, even though Dyne’s own upcoming one-year data have not yet been released. RTT News report on rival DM1 failure
• Negative Sentiment: Several executives, including CEO John Cox, reported stock sales. The transactions were made to cover tax withholding on vested equity awards and were relatively small compared with their remaining holdings, limiting their direct significance, but the cluster of sales may add to cautious sentiment.

Wall Street Analyst Weigh In

DYN has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th. Royal Bank Of Canada increased their price target on Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, July 30th. Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Evercore set a $33.00 price objective on Dyne Therapeutics in a research report on Friday, May 15th. Finally, Sanford C. Bernstein upped their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.